Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Collaboration with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney (UNSW) has been extended from February 2023 through to January 2025 to evaluate the efficacy of Nyrada’s brain injury drug candidate to reduce secondary brain damage following a traumatic brain injury (TBI).
~5.5 million people suffer a severe traumatic brain injury (TBI) each year, making TBI a serious and life-threatening condition with significant unmet clinical need.
The collaboration aligns with WRAIR's mission to develop ground-breaking solutions to mitigate the impact of TBIs which affect 1 in 25 US military service members.